Related Experiment Video
Updated: Feb 14, 2026

Radiosensitivity of Cancer Stem Cells in Lung Cancer Cell Lines
Published on: August 21, 2019
[Non-Small Cell Lung Cancer - Development of Parallel Mechanisms of Resistance]
M Moeller1, U Siebolts2, C Wickenhauser2
1Klinik für Innere Medizin II, Krankenhaus Martha-Maria Halle-Dölau.
Abstract:
Acquired resistances to tyrosine kinase inhibitors in non-small cell lung cancer develop after 9 - 12 month. In 60 % of the cases these resistances arise because of a secondary EGFR-T790 M resistance mutation. This report is describing the case of a patient who developed parallel two different mechanisms of resistance: A T790 M resistance mutation and a transformation into a small cell neuroendocrine cancer. Under therapy with Osimertinib and chemotherapy with carboplatin and etoposide the tumor responsed partially.
Insights
Acquired resistance to lung cancer drugs is common. This case shows a patient developing two resistance types simultaneously: an EGFR mutation and cancer transformation, with partial response to treatment.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Non-small cell lung cancer (NSCLC) frequently develops resistance to tyrosine kinase inhibitors (TKIs) within 9-12 months.
- The EGFR T790M mutation is a common cause (60%) of acquired resistance in NSCLC patients.
Observation:
- This report details a unique NSCLC case with concurrent development of two distinct resistance mechanisms.
- The patient exhibited both the EGFR T790M resistance mutation and a histological transformation to small cell neuroendocrine carcinoma.
Findings:
- The patient received Osimertinib combined with carboplatin and etoposide chemotherapy.
- A partial response of the tumor to the combined therapy was observed despite the dual resistance mechanisms.
Implications:
- This case highlights the complex resistance pathways in NSCLC, including co-occurring genetic mutations and histological changes.
- Understanding these parallel resistance mechanisms is crucial for developing more effective, personalized treatment strategies for advanced NSCLC.
- Further research is needed to explore therapeutic approaches for patients with combined resistance profiles.
More Related Videos
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
06:12Author Spotlight: Optimizing Bovine Lung Decellularization for Organotypic Hydrogels
Published on: December 8, 2023
Related Concept Videos
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Development of Antibiotic Resistance
Treatment Resistant Cancers
Mechanisms of Retrovirus-induced Cancers
Parallel Processing
Parallel Resonance